These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 23802073)

  • 1. HEPA and PARSE: Systematic discovery of clinically relevant tumor-specific antigens.
    Xu QW; Zhang Y; Wang XS
    Oncoimmunology; 2013 Mar; 2(3):e23249. PubMed ID: 23802073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying autoantibody signatures in cancer: a promising challenge.
    Desmetz C; Maudelonde T; Mangé A; Solassol J
    Expert Rev Proteomics; 2009 Aug; 6(4):377-86. PubMed ID: 19681673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mouse Hepa-1 tumor is rejected by H-2Db-restricted CTL despite decreased MHC class I antigen expression.
    Nishimura MI; Ostrand-Rosenberg S
    Cell Immunol; 1991 Sep; 136(2):414-24. PubMed ID: 1908353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibody signatures: progress and perspectives for early cancer detection.
    Desmetz C; Mange A; Maudelonde T; Solassol J
    J Cell Mol Med; 2011 Oct; 15(10):2013-24. PubMed ID: 21651719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-scale search of tumor-specific antigens by collective analysis of mutations, expressions and T-cell recognition.
    Jia J; Cui J; Liu X; Han J; Yang S; Wei Y; Chen Y
    Mol Immunol; 2009 May; 46(8-9):1824-9. PubMed ID: 19243822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of antibody biomarkers using protein microarrays of tumor antigens cloned in high throughput.
    Chatterjee M; Wojciechowski J; Tainsky MA
    Methods Mol Biol; 2009; 520():21-38. PubMed ID: 19381945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigen arrays for profiling autoantibody repertoires.
    Ayoglu B; Schwenk JM; Nilsson P
    Bioanalysis; 2016 May; 8(10):1105-26. PubMed ID: 27097564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteogenomics Uncovers a Vast Repertoire of Shared Tumor-Specific Antigens in Ovarian Cancer.
    Zhao Q; Laverdure JP; Lanoix J; Durette C; Côté C; Bonneil É; Laumont CM; Gendron P; Vincent K; Courcelles M; Lemieux S; Millar DG; Ohashi PS; Thibault P; Perreault C
    Cancer Immunol Res; 2020 Apr; 8(4):544-555. PubMed ID: 32047025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noncoding regions are the main source of targetable tumor-specific antigens.
    Laumont CM; Vincent K; Hesnard L; Audemard É; Bonneil É; Laverdure JP; Gendron P; Courcelles M; Hardy MP; Côté C; Durette C; St-Pierre C; Benhammadi M; Lanoix J; Vobecky S; Haddad E; Lemieux S; Thibault P; Perreault C
    Sci Transl Med; 2018 Dec; 10(470):. PubMed ID: 30518613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies.
    Janelle V; Rulleau C; Del Testa S; Carli C; Delisle JS
    Front Immunol; 2020; 11():276. PubMed ID: 32153583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic approaches for biologic therapy of cancer.
    Gambotto A; Cicinnati V; Robbins PD
    Drugs Today (Barc); 2000 Jan; 36(1):25-39. PubMed ID: 12879102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer.
    Wang P; Qin J; Ye H; Li L; Wang X; Zhang J
    J Cell Biochem; 2019 Mar; 120(3):3091-3100. PubMed ID: 30484895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes.
    Ehx G; Larouche JD; Durette C; Laverdure JP; Hesnard L; Vincent K; Hardy MP; Thériault C; Rulleau C; Lanoix J; Bonneil E; Feghaly A; Apavaloaei A; Noronha N; Laumont CM; Delisle JS; Vago L; Hébert J; Sauvageau G; Lemieux S; Thibault P; Perreault C
    Immunity; 2021 Apr; 54(4):737-752.e10. PubMed ID: 33740418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer.
    Philip R; Murthy S; Krakover J; Sinnathamby G; Zerfass J; Keller L; Philip M
    J Proteome Res; 2007 Jul; 6(7):2509-17. PubMed ID: 17547437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-based identification of cell surface antigens: targets for cancer therapy.
    Loo DT; Mather JP
    Curr Opin Pharmacol; 2008 Oct; 8(5):627-31. PubMed ID: 18804182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoproteomics to identify tumor-associated antigens eliciting humoral response.
    Mou Z; He Y; Wu Y
    Cancer Lett; 2009 Jun; 278(2):123-129. PubMed ID: 18930343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunotherapy: new insights].
    Geissler M; Weth R
    Praxis (Bern 1994); 2002 Dec; 91(51-52):2236-46. PubMed ID: 12564040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a high throughput system for discovery of antigens for autoantibody detection.
    Macdonald IK; Allen J; Murray A; Parsy-Kowalska CB; Healey GF; Chapman CJ; Sewell HF; Robertson JF
    PLoS One; 2012; 7(7):e40759. PubMed ID: 22815807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal serum autoantibody repertoire profiling identifies surgery-associated biomarkers in lung adenocarcinoma.
    Li Y; Li CQ; Guo SJ; Guo W; Jiang HW; Li HC; Tao SC
    EBioMedicine; 2020 Mar; 53():102674. PubMed ID: 32113159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug development for cancer chemoprevention: focus on molecular targets.
    Johnson KA; Brown PH
    Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.